The Diagnosis and Treatment of Fibromuscular Dysplasia: An Update for Cardiologists

Vascular Disease (I Weinberg, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Vascular Disease

Opinion statement

Fibromuscular dysplasia (FMD) is an arteriopathy of unknown etiology which has traditionally been associated with secondary hypertension; however, it has garnered increased attention in the cardiology field in the recent years because of its potential association with spontaneous coronary artery dissection. Cardiologists should be aware that FMD is a polyvascular disease which can affect any arterial bed and can result in morbid conditions such as chronic headaches, pulsatile tinnitus, stroke from cervical artery dissection, and renal infarction from renal artery dissection and has also been associated with increased prevalence of arterial aneurysm, including brain aneurysm. For these reasons, some experts recommend panvascular imaging from head-to-pelvis upon diagnosis for screening purposes and targeted imaging surveillance after diagnosis. When necessary, endovascular intervention with angioplasty alone is the preferred modality, though there are still situations which require surgical intervention. Patients with FMD may benefit from a multispecialty team approach for optimal treatment.

Keywords

Fibromuscular dysplasia Vascular disease 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:••Of major importance

  1. 1.••
    Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014;129(9):1048–78. Class IV - This provides a thorough review of the history, clinical presentation, and management of FMD.CrossRefPubMedGoogle Scholar
  2. 2.••
    Olin JW, Froehlich J, Gu X, et al. The United States registry for fibromuscular dysplasia: results in the first 447 patients. Circulation. 2012;125(25):3182–90. Class III - This publication lays the groundwork for a large degree of what we currently know about the clinical presentation of FMD. It was the first large scale assessment of patients with FMD and has shed light on the clinical presentation of these patients.CrossRefPubMedGoogle Scholar
  3. 3.••
    O’Connor S, Kim ES, Brinza E, et al. Systemic connective tissue features in women with fibromuscular dysplasia. Vasc Med. 2015;20(5):454–62. Class III - Authors attempt to evaluate the etiology of FMD by evaluating for connective tissue features in patients with FMD.CrossRefPubMedGoogle Scholar
  4. 4.••
    Saw J, Ricci D, Starovoytov A, Fox R, Buller CE. Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. J Am Coll Cardiol Intv. 2013;6(1):44–52. Class III - Investigators help better characterize patients that are affected by SCAD and in turn, help recognize SCAD to the right patient population.CrossRefGoogle Scholar
  5. 5.
    Leadbetter W, Burkland CE. Hypertension in unilateral renal disease. J Urol. 1938;39(61):1–626.Google Scholar
  6. 6.
    McKenzie GA, Oderich GS, Kawashima A, Misra S. Renal artery fibromuscular dysplasia in 2,640 renal donor subjects: a CT angiography analysis. J Vasc Interv Radiol. 2013;24(10):1477–80.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Neymark E, LaBerge JM, Hirose R, et al. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery 1. Radiology. 2000;214(3):755–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Hendricks NJ, Matsumoto AH, Angle JF, et al. Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution population of renal donor candidates. Vasc Med. 2014;19(5):363–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Schievink WI, Bjornsson J. Fibromuscular dysplasia of the internal carotid artery: a clinicopathological study. Clin Neuropathol. 1996;15(1):2–6.PubMedGoogle Scholar
  10. 10.
    Touzé E, Oppenheim C, Trystram D, et al. Fibromuscular dysplasia of cervical and intracranial arteries. Int J Stroke. 2010;5(4):296–305.CrossRefPubMedGoogle Scholar
  11. 11.
    Kadian-Dodov D, Gornik H, Gu X, et al. Aneurysm and dissection in fibromuscular dysplasia: findings from the united states registry for FMD. J Am Coll Cardiol. 2014;63(12_S). doi:10.1016/S0735-1097(14)62033-7.
  12. 12.••
    Kim ES, Olin JW, Froehlich JB, et al. Clinical manifestations of fibromuscular dysplasia vary by patient sex: a report of the united states registry for fibromuscular dysplasia. J Am Coll Cardiol. 2013;62(21):2026–8. Class III -Investigators delineate the differences in presentation between men and women in FMD.CrossRefPubMedGoogle Scholar
  13. 13.
    Saw J, Aymong E, Mancini GJ, Sedlak T, Starovoytov A, Ricci D. Nonatherosclerotic coronary artery disease in young women. Can J Cardiol. 2014;30(7):814–9.CrossRefPubMedGoogle Scholar
  14. 14.••
    Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012;126(5):579–88. Class III - Investigators reviewed the clinical presentation of patients with SCAD and the differences of in the outcomes with different management strategies.CrossRefPubMedGoogle Scholar
  15. 15.
    Saw J, Aymong E, Sedlak T, et al. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv. 2014;7(5):645–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Saw J. Coronary angiogram classification of spontaneous coronary artery dissection. Catheter Cardiovasc Interv. 2014;84(7):1115–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Sang CN, Whelton PK, Hamper UM, et al. Etiologic factors in renovascular fibromuscular dysplasia. A case-control study. Hypertension. 1989;14(5):472–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Savard S, Azarine A, Jeunemaitre X, Azizi M, Plouin PF, Steichen O. Association of smoking with phenotype at diagnosis and vascular interventions in patients with renal artery fibromuscular dysplasia. Hypertension. 2013;61(6):1227–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Rushton AR. The genetics of fibromuscular dysplasia. Arch Intern Med. 1980;140(2):233.CrossRefPubMedGoogle Scholar
  20. 20.
    Ganesh SK, Morissette R, Xu Z, et al. Clinical and biochemical profiles suggest fibromuscular dysplasia is a systemic disease with altered TGF-beta expression and connective tissue features. FASEB J. 2014;28(8):3313–24.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Silhol F, Sarlon-Bartoli G, Daniel L, et al. Intranuclear expression of progesterone receptors in smooth muscle cells of renovascular fibromuscular dysplasia: a pilot study. Ann Vasc Surg. 2015;29(4):830–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Prasad A, Zafar N, Mahmud E. Assessment of renal artery fibromuscular dysplasia: angiography, intravascular ultrasound (with virtual histology), and pressure wire measurements. Catheter Cardiovasc Interv. 2009;74(2):260–4.PubMedGoogle Scholar
  23. 23.
    Gowda MS, Loeb AL, Crouse LJ, Kramer PH. Complementary roles of color-flow duplex imaging and intravascular ultrasound in the diagnosis of renal artery fibromuscular dysplasia: should renal arteriography serve as the “gold standard”? J Am Coll Cardiol. 2003;41(8):1305–11.CrossRefPubMedGoogle Scholar
  24. 24.••
    Persu A, Giavarini A, Touze E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens. 2014;32(7):1367–78. Class IV - This provides a concise review of the new findings in FMD and helps guide management, with insight into appropriate imaging and insight with regards to which patients should undergo intervention.CrossRefPubMedGoogle Scholar
  25. 25.
    Quirk K, Bandyk DF. Interpretation of carotid duplex testing. Semin Vasc Surg. 2013;26(2):72-85. doi: 10.1053/j.semvascsurg.2014.01.003.
  26. 26.
    O’Connor SC, Gornik HL. Recent developments in the understanding and management of fibromuscular dysplasia. J Am Heart Assoc. 2014;3(6):e001259.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sabharwal R, Vladica P, Coleman P. Multidetector spiral CT renal angiography in the diagnosis of renal artery fibromuscular dysplasia. Eur J Radiol. 2007;61(3):520–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Willoteaux S, Faivre-Pierret M, Moranne O, et al. Fibromuscular dysplasia of the main renal arteries: comparison of contrast-enhanced MR angiography with digital subtraction angiography 1. Radiology. 2006;241(3):922–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Heiserman JE, Drayer BP, Fram EK, Keller PJ. MR angiography of cervical fibromuscular dysplasia. AJNR Am J Neuroradiol. 1992;13(5):1454–7.PubMedGoogle Scholar
  30. 30.
    Furie DM, Tien RD. Fibromuscular dysplasia of arteries of the head and neck: imaging findings. AJR Am J Roentgenol. 1994;162(5):1205–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25_PA):2960–84.CrossRefPubMedGoogle Scholar
  32. 32.
    Siu AL. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: US preventive services task force recommendation statement. Ann Intern Med. 2015;163(8):622–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Poloskey SL, Olin JW, Mace P, Gornik HL. Fibromuscular dysplasia. Circulation. 2012;125(18):e636–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Weinberg I, Gu X, Giri J, et al. Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: results from the United States registry for fibromuscular dysplasia. Vasc Med. 2015;20(5):447–53.CrossRefPubMedGoogle Scholar
  35. 35.
    Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral ar. J Am Coll Cardiol. 2011;57(8):e16–94.CrossRefPubMedGoogle Scholar
  36. 36.
    Beletsky V, Nadareishvili Z, Lynch J, Shuaib A, Woolfenden A, Norris JW. Cervical arterial dissection time for a therapeutic trial? Stroke. 2003;34(12):2856–60.CrossRefPubMedGoogle Scholar
  37. 37.
    Biousse V, D’Anglejan-Chatillon J, Touboul PJ, Amarenco P, Bousser MG. Time course of symptoms in extracranial carotid artery dissections. A series of 80 patients. Stroke. 1995;26(2):235–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Weimar C, Kraywinkel K, Hagemeister C, et al. Recurrent stroke after cervical artery dissection. J Neurol Neurosurg Psychiatry. 2010;81(8):869–73.CrossRefPubMedGoogle Scholar
  39. 39.
    Trial Investigators CADISS. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015;14(4):361–7.CrossRefGoogle Scholar
  40. 40.
    Chowdhury M, Sabbagh C, Jackson D, Coughlin P, Ghosh J. Antithrombotic treatment for acute extracranial carotid artery dissections: a meta-analysis. Eur J Vasc Endovasc Surg. 2015;50(2):148–56.CrossRefPubMedGoogle Scholar
  41. 41.
    Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. The Cochrane database of systematic reviews. 2010:CD000255.Google Scholar
  42. 42.
    Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–75.CrossRefPubMedGoogle Scholar
  43. 43.
    Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1: epidemiology, pathogenesis, and clinical course. AJNR Am J Neuroradiol. 2015;36(8):1392–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache. 2004;44(s1):S20–30.CrossRefPubMedGoogle Scholar
  45. 45.
    Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35(2):118–31.CrossRefPubMedGoogle Scholar
  46. 46.
    Dennison-Himmelfarb C, Handler J, Lackland DT, et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth joint national committee (JNC 8). 2013.Google Scholar
  47. 47.
    Stone NJ, Merz CNB, ScM F, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. 2013.Google Scholar
  48. 48.
    Persu A, Touzé E, Mousseaux E, Barral X, Joffre F, Plouin P. Diagnosis and management of fibromuscular dysplasia: an expert consensus. Eur J Clin Invest. 2012;42(3):338–47.CrossRefPubMedGoogle Scholar
  49. 49.
    Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; TransAtlantic inter-society consensus; and vascular disease foundation. Circulation. 2006;113(11):e463–654.CrossRefPubMedGoogle Scholar
  50. 50.
    Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension. 2010;56(3):525–32.CrossRefPubMedGoogle Scholar
  51. 51.
    Mousa AY, Campbell JE, Stone PA, Broce M, Bates MC, AbuRahma AF. Short-and long-term outcomes of percutaneous transluminal angioplasty/stenting of renal fibromuscular dysplasia over a ten-year period. J Vasc Surg. 2012;55(2):421–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898–906.CrossRefPubMedGoogle Scholar
  53. 53.
    Edgell RC, Abou-Chebl A, Yadav JS. Endovascular management of spontaneous carotid artery dissection. J Vasc Surg. 2005;42(5):854–60.CrossRefPubMedGoogle Scholar
  54. 54.
    Wiebers DO. International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103–10.CrossRefPubMedGoogle Scholar
  55. 55.
    Japan Investigators UCAS, Morita A, Kirino T, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med. 2012;366(26):2474–82.CrossRefGoogle Scholar
  56. 56.
    Raja PV, Huang J, Germanwala AV, Gailloud P, Murphy KP, Tamargo RJ. Microsurgical clipping and endovascular coiling of intracranial aneurysms: a critical review of the literature. Neurosurgery. 2008;62(6):1187–203.CrossRefPubMedGoogle Scholar
  57. 57.
    Molyneux AJ, Birks J, Clarke A, Sneade M, Kerr RS. The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the international subarachnoid aneurysm trial (ISAT). Lancet. 2015;385(9969):691–7.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Komotar RJ, Mocco J, Solomon RA. Guidelines for the surgical treatment of unruptured intracranial aneurysms: the First Annual J. Lawrence Pool Memorial Research Symposium—controversies in the management of cerebral aneurysms. Neurosurgery. 2008;62(1):183–93. discussion 193-4.CrossRefPubMedGoogle Scholar
  59. 59.
    Tweet MS, Eleid MF, Best PJ, et al. Spontaneous coronary artery dissection: revascularization versus conservative therapy. Circ Cardiovasc Interv. 2014;7(6):777–86.CrossRefPubMedGoogle Scholar
  60. 60.
    Stanley JC, Henke P. Renal artery bypass. In: Lumley JS, Hoballab JJ, editors. Vascular Surgery: Springer Surgery Atlas Series. Berlin, Germany: Springer-Verlag; 2009. p. 241–56.Google Scholar
  61. 61.
    Stanley JC, Ernst CB, Fry WJ. Fate of 100 aortorenal vein grafts: characteristics of late graft expansion, aneurysmal dilatation, and stenosis. Surgery. 1973;74(6):931–44.PubMedGoogle Scholar
  62. 62.
    Stanley JC, Criado E, Upchurch GR, et al. Pediatric renovascular hypertension: 132 primary and 30 secondary operations in 97 children. J Vasc Surg. 2006;44(6):1219–28.CrossRefPubMedGoogle Scholar
  63. 63.
    Crutchley TA, Pearce JD, Craven TE, Edwards MS, Dean RH, Hansen KJ. Branch renal artery repair with cold perfusion protection. J Vasc Surg. 2007;46(3):405–12. e2.CrossRefPubMedGoogle Scholar
  64. 64.
    Chiche L, Kieffer E, Sabatier J, Colau A, Koskas F, Bahnini A. Renal autotransplantation for vascular disease: late outcome according to etiology. J Vasc Surg. 2003;37(2):353–61.CrossRefPubMedGoogle Scholar
  65. 65.
    Balzer KM, Neuschäfer S, Sagban T, et al. Renal artery revascularization after unsuccessful percutaneous therapy: a single centre experience. Langenbeck’s Arch Surg. 2012;397(1):111–5.CrossRefGoogle Scholar
  66. 66.
    Liang P, Hurks R, Bensley RP, et al. The rise and fall of renal artery angioplasty and stenting in the United States, 1988-2009. J Vasc Surg. 2013;58(5):1331–8. e1.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Cleveland Clinic Lerner College of Medicine of Case Western Reserve UniversityClevelandUSA
  2. 2.Cardiovascular Medicine, Heart and Vascular InstituteCleveland ClinicClevelandUSA

Personalised recommendations